African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

• Published in: Journal of viral hepatitis Vol. 8; no. 4; pp. 264 - 269
• Main Authors: Kinzie, J. L., Naylor, P. H., Nathani, M. G., Peleman, R. R., Ehrinpreis, M. N., Lybik, M., Turner, J. R., Janisse, J. J., Massanari, M., Mutchnick, M. G.
• Format: Journal Article
• Language: English
• Published: Oxford UK Blackwell Science Ltd 01.07.2001
• Subjects: Adult; African Americans; African Continental Ancestry Group; Chronic Disease; European Continental Ancestry Group; Female; Genotype; Hepacivirus - genetics; hepatitis C; Hepatitis C virus; Hepatitis C, Chronic - therapy; Humans; interferon; Interferons - therapeutic use; Male; Middle Aged; Prognosis; race; Retrospective Studies; RNA, Viral - analysis; United States; United States
• DOI: 10.1046/j.1365-2893.2001.00292.x
• ISSN: 1352-0504

African Americans as a group have a higher incidence of chronic hepatitis C (CHC) than Caucasians but are often under‐represented in clinical trials used to define response rates to interferon therapy. The aim of this study was to compare African Americans with Caucasians with respect to end‐of‐treatment response to interferon. This retrospective study had 61 African Americans and 49 Caucasians with CHC. All patients were treated for at least 12 weeks with interferon‐α2b (Intron A) thrice weekly. End‐of‐treatment response was defined as three consecutive nondetectable HCV RNA measurements at least 1 month apart. Sustained response was defined as a negative serum HCV RNA 6 months after end of treatment. Of the 110 patients, 19 achieved an end‐of‐treatment response (17%) but only four achieved a sustained response (4/110=4%). Of the patients achieving a sustained response, one was genotype 1 (male Caucasian), three were genotype 2/3 with four patients having no follow‐up information. The end‐of‐treatment response was 7% for patients with genotype 1 and 71% for genotype non‐1 (P < 0.005 for genotype non‐1). The end‐of‐treatment response was significantly higher in Caucasians (14/49=31%) compared with African Americans (5/61=8%; P < 0.05). A lower response rate in African Americans with genotype 1 in contrast to Caucasians was the primary reason for the difference in end‐of‐treatment response (1/45=2% vs. 5/33=15%, P < 0.05). Hence, interferon treatment resulted in a poor sustained response rate in the group of patients representative of the urban populations with the highest prevalence of hepatitis C. A genotype other than type 1 was the strongest predictor of end‐of‐treatment response in patients treated but over 86% of patients in this urban clinic were genotype 1. Caucasians were more likely to respond than African Americans, especially in patients with genotype 1.